Kezar Life Sciences, Inc. (KZR)
NASDAQ: KZR · Real-Time Price · USD
7.40
0.00 (0.00%)
At close: Apr 2, 2026, 4:00 PM EDT
7.50
+0.10 (1.30%)
After-hours: Apr 2, 2026, 4:51 PM EDT

Kezar Life Sciences Income Statement

Millions USD. Fiscal year is Jan - Dec.
Fiscal Year
FY 2025FY 2024FY 2023FY 2022FY 2021
Period Ending
Dec '25 Dec '24 Dec '23 Dec '22 Dec '21
--7--
Gross Profit
--7--
Selling, General & Admin
18.5123.3926.5420.1515.72
Research & Development
33.7665.7485.751.0138.94
Other Operating Expenses
6.841.476.19--
Total Operating Expenses
59.1190.61118.4271.1654.66
Operating Income
-59.11-90.61-111.42-71.16-54.66
Interest Income
4.448.4611.14.110.19
Interest Expense
-1.37-1.59-1.55-1.19-0.16
Total Non-Operating Income (Expense)
3.076.879.552.920.03
Pretax Income
-56.03-83.74-101.87-68.24-54.63
Net Income
-56.03-83.74-101.87-68.24-54.63
Net Income to Common
-56.03-83.74-101.87-68.24-54.63
Shares Outstanding (Basic)
77775
Shares Outstanding (Diluted)
77775
Shares Change (YoY)
0.36%0.48%7.70%27.69%19.90%
EPS (Basic)
-7.66-11.49-14.04-10.13-10.40
EPS (Diluted)
-7.66-11.49-14.04-10.13-10.40
Shares Outstanding
7.327.37.286.855.63
Free Cash Flow
-51.79-74.24-83.46-60.42-42.75
Free Cash Flow Per Share
-7.08-10.18-11.50-8.97-8.10
Gross Margin
--100.00%--
Operating Margin
---1591.77%--
Profit Margin
---1455.29%--
FCF Margin
---1192.21%--
EBITDA
-58.21-89.57-110.36-70.14-53.15
EBITDA Margin
---1576.54%--
EBIT
-59.11-90.61-111.42-71.16-54.66
EBIT Margin
---1591.77%--
Updated Dec 31, 2025. Data Source: Fiscal.ai. Standard template. Financial Sources.
SEC Filings: 10-K · 10-Q